Skip to main content

Generic Daurismo Availability

Last updated on Oct 6, 2021.

Daurismo is a brand name of glasdegib, approved by the FDA in the following formulation(s):

DAURISMO (glasdegib maleate - tablet;oral)

  • Manufacturer: PFIZER
    Approval date: November 21, 2018
    Strength(s): EQ 25MG BASE [RLD], EQ 100MG BASE [RLD]

Has a generic version of Daurismo been approved?

No. There is currently no therapeutically equivalent version of Daurismo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Daurismo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,414,748

    Patent expiration dates:

    • April 13, 2036
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Benzimidazole derivatives
    Patent 8,148,401
    Issued: April 3, 2012
    Inventor(s): Munchhof; Michael J. & Reiter; Lawrence A. & La Greca; Susan D. & Jones; Christopher S. & Li; Qifang
    Assignee(s): Pfizer Inc.

    The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

    Patent expiration dates:

    • January 30, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Benzimidazole derivatives
    Patent 8,431,597
    Issued: April 30, 2013
    Assignee(s): Pfizer Inc.

    The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

    Patent expiration dates:

    • June 29, 2028
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • November 21, 2023 - NEW CHEMICAL ENTITY
    • November 21, 2025 -

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.